August 5, 2022
Good for Bladder Cancer, Better for Kidney Cancer BookmarkGeorge Lundberg, MD
This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.
December 2, 2019
Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers BookmarkGeorge Lundberg, MD
Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes:
In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.